BioNTech CFO Calls A Deal With Founders' New Company 'Optional' As Sahin And Tureci Hold Last Call

Talks continue on a tie-up with the co-founders' new venture, but CFO Ramon Zapata said it is not a necessity.

Share
BioNTech CFO Calls A Deal With Founders' New Company 'Optional' As Sahin And Tureci Hold Last Call

BioNTech Chief Financial Officer Ramon Zapata said on the company's third-quarter earnings call Tuesday that talks over a deal with the new company of co-founders Ugur Sahin and Ozlem Tureci are ongoing, but that an agreement is "optional for both parties and not a necessity." It was the last earnings call for the pair, who are leaving operational roles.

Founders' new company, and a deal that is optional

BioNTech, the Mainz-based immunotherapy company focused on cancer medicines, is in discussions about "potential contributions from BioNTech" to the founders' new venture, Zapata said. Any arrangement will be judged on its strategic rationale and its ability to maximize value for patients and shareholders, he said.

Earlier reports said BioNTech planned to contribute rights and mRNA technologies to the new Mainz-based company, Arife, in exchange for a minority stake and licensing fees, according to a Süddeutsche Zeitung report.

Chief Executive Ugur Sahin said "this will be my last earnings call." He and Tureci, the chief medical officer, will keep following BioNTech as founding shareholders, he said, and a successor CEO will take office by February 1 at the latest.

Revenue of €1.3 billion and a higher midpoint

Third-quarter revenue was €1.3 billion, against €1.5 billion a year earlier, which Zapata attributed mainly to lower expected demand for the COVID-19 vaccine. The quarter included €613 million from the Pumitamig partnership with Bristol Myers Squibb's collaboration, he said.

The company now guides to €1.7 billion to €1.9 billion in 2026 revenue, a higher midpoint. Adjusted R&D guidance stays at €2 billion to €2.3 billion and SG&A at €700 million to €800 million.

BioNTech ended the quarter with €16.2 billion in cash, cash equivalents and security investments. It has bought back about 5 million shares through September 30 since starting its buyback in June, Zapata said.

Gotistobart's early look

Tureci said the first interim analysis of the lung cancer drug gotistobart, expected before year-end, is early. "We will not be disappointed if we cannot see a clear signal," she said. The company has not had detailed discussions with regulators and will engage after the second part of the trial, she said.

At the World Conference on Lung Cancer, median overall survival in the trial's early portion was 18.5 months with gotistobart versus 10 months with docetaxel chemotherapy.

The next marker is the gotistobart interim analysis due before year-end, with a second planned interim analysis next year.

Sources

More on BioNTech

All BioNTech (BNTX) coverage →